Late-onset scleroderma renal crisis induced by tacrolimus and prednisolone: A case report

American Journal of Therapeutics

Volumn 21, Issue 5, 2014, Pages e130-e133

  Nunokawa, Takahiro ^a   Akazawa, Masanobu ^b   Yokogawa, Naoto ^a   Shimada, Kota ^a   Hiramatsu, Kazuko ^c   Nishio, Yasuhide ^a   Sugii, Shoji ^a  

^a TOKYO METROPOLITAN TAMA MEDICAL CENTER   (Japan)

^b TOKYO KYOSAI HOSPITAL   (Japan)

^c Hiramatsu Naika Clinic   (Japan)

Author keywords

Prednisolone; Scleroderma renal crisis; Systemic sclerosis; Tacrolimus; Thrombotic microangiopathy

Indexed keywords

ALDOSTERONE; ANTINUCLEAR ANTIBODY; CAPTOPRIL; NICARDIPINE; PREDNISOLONE; RENIN; TACROLIMUS;

ACUTE KIDNEY FAILURE; AGED; ALDOSTERONE BLOOD LEVEL; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CASE REPORT; CORTICOSTEROID THERAPY; COUGHING; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEMODIALYSIS; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY DISEASE; MAINTENANCE DRUG DOSE; MALIGNANT HYPERTENSION; PLASMA RENIN ACTIVITY; PLASMAPHERESIS; SCLERODERMA; SCLERODERMA RENAL CRISIS; SKIN EDEMA; SYSTEMIC SCLEROSIS; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; CHEMICALLY INDUCED; COMPLICATION;

ACUTE KIDNEY INJURY; AGED; FEMALE; HUMANS; PREDNISOLONE; SCLERODERMA, SYSTEMIC; TACROLIMUS; THROMBOTIC MICROANGIOPATHIES;

EID: 84913604221     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3182583ba1     Document Type: Article

References (15)

1. Denton CP, Lapadula G, Mouthon L, et al. Renal complications and scleroderma renal crisis. Rheumatology (Oxford). 2009;48(suppl 3):iii32-iii35.
2. Sato S, Fujimoto M, Kuwana M, et al. The treatment guideline of systemic sclerosis [in Japanese]. Scleroderma Study Conference web site. Available at: http://derma. w3.kanazawa-u.ac.jp/SSc/SSc.html. Accessed March 19, 2012.
3. Teixeira L, Mouthon L, Mahr A, et al; Group Franxcais de Recherche sur le Sclérodermie (GFRS). Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann Rheum Dis. 2008;67:110-116.
4. Trang G, Steele R, Baron M, et al. Corticosteroids and the risk of scleroderma renal crisis: a systematic review. Rheumatol Int. 2012;32:645-653.
5. Steen VD, Medsger TA Jr. Case-control study of cortico-steroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum. 1998;41:1613-1619.
6. Morton SJ, Powell RJ. Cyclosporin and tacrolimus: their use in a routine clinical setting for scleroderma. Rheumatology (Oxford). 2000;39:865-869.
7. Ponticelli C. De novo thrombotic microangiopathy. An underrated complication of renal transplantation. Clin Nephrol. 2007;67:335-340.
8. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4:481-508.
9. Bren A, Pajek J, Grego K, et al. Follow-up of kidney graft recipients with cyclosporine-associated hemolytic-uremic syndrome and thrombotic microangiopathy. Transplant Proc. 2005;37:1889-1891.
10. Denton CP, Sweny P, Abdulla A, et al. Acute renal failure occurring in scleroderma treated with cyclosporin A: a report of three cases. Br J Rheumatol. 1994;33:90.
11. Zachariae H, Hansen HE, Olsen TS. Hemolytic uremic syndrome in a patient with systemic sclerosis treated with cyclosporin A. Acta Derm Venereol. 1992;72:307-309.
12. Trimarchi HM, Truong LD, Brennan S, et al. FK506-associated thrombotic microangiopathy: report of two cases and review of the literature. Transplantation. 1999;67: 539-544.
13. Lin CC, King KL, Chao YW, et al. Tacrolimus-associated hemolytic uremic syndrome: a case analysis. J Nephrol. 2003;16:580-585.
14. Batal I, Domsic RT, Medsger TA, et al. Scleroderma renal crisis: a pathology perspective. Int J Rheumatol. 2010;2010: 543704.
15. Bussone G, Bérezné A, Pestre V, et al. The scleroderma kidney: progress in risk factors, therapy, and prevention. Curr Rheumatol Rep. 2011;13:37-43.